|
WO2021068074A1
|
|
Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
|
|
CA3113539A1
|
|
Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
|
|
CN112020519A
|
|
anti-HER 2 biparatopic antibody-drug conjugates and methods of use
|
|
AU2018292438A1
|
|
Stabilized chimeric fabs
|
|
BR112019020456A2
|
|
constructs inducing the presentation of tumor antigen and their uses
|
|
US2018193473A1
|
|
Compositions and methods for the treatment of platinum-drug resistant cancer
|
|
WO2017185177A1
|
|
Methods of using bispecific antigen-binding constructs targeting her2
|
|
CN109153727A
|
|
Target the polyspecific antigen-binding constructs of immunotherapeutic agent
|
|
CN108283001A
|
|
Include the antigen-binding polypeptides construct and application thereof of κ and lambda light chain
|
|
CA2944318A1
|
|
Compositions and methods for the treatment of platinum-drug resistant cancer
|
|
WO2017054080A1
|
|
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
|
US2017053063A1
|
|
Methods For Determining Correlated Residues In A Protein Or Other Biopolymer Using Molecular Dynamics
|
|
EP3322735A1
|
|
Drug-conjugated bi-specific antigen-binding constructs
|
|
US2018273635A1
|
|
Antigen-Binding Constructs Targeting HER2
|
|
AU2015354360A1
|
|
Methods of using bispecific antigen-binding constructs targeting HER2
|
|
US2016075735A1
|
|
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
|
US2017204199A1
|
|
Modified antigen binding polypeptide constructs and uses thereof
|
|
CN106661121A
|
|
Modified antigen binding polypeptide constructs and uses thereof
|
|
AU2015265457A1
|
|
Modified antigen binding polypeptide constructs and uses thereof
|
|
KR20160107304A
|
|
Bi-specific cd3 and cd19 antigen-binding constructs
|
